New Research Uncovers Blood Changes in Rheumatoid Arthritis Risk: Key Insights for Early Detection

New Blood Test May Predict Risk of Rheumatoid Arthritis

Researchers from HSS and other institutions have found specific immune cell patterns in blood that may indicate a higher risk of developing rheumatoid arthritis (RA) before symptoms arise. This discovery aims to lead to a blood test that helps doctors identify patients at risk for the disease.

The study was presented at ACR Convergence 2024 and led by the University of Colorado School of Medicine in collaboration with HSS and other centers in the Accelerating Medicines Partnership Program: RA and Systemic Lupus Erythematosus Network.

Dr. Laura Donlin, co-director of the HSS Precision Medicine Program and co-principal investigator, stated, “These findings highlight how certain immune cells influence the transition from being asymptomatic to symptomatic. We hope to prevent RA before it starts.”

Rheumatoid arthritis is an inflammatory arthritis that occurs when immune cells attack healthy tissues, causing pain and swelling in joints. It can also affect other body areas like the heart and lungs. Diagnosis usually involves evaluations by rheumatologists supported by X-rays and blood tests.

For this study, rheumatologists gathered tissue and blood samples from RA patients and those at risk, identified by specific antibodies in their blood and having a first-degree relative with RA. Researchers at the Broad Institute of MIT and Harvard analyzed these samples using advanced single-cell sequencing techniques and compared them to samples from healthy individuals.

The analysis revealed higher levels of certain immune cells in patients at risk for RA, including CCR2+ T helper cells and granzyme B-positive memory T helper cells. It also provided insights into gene activation in these cells, showing how immune responses differ across at-risk individuals and healthy people.

Dr. Susan M. Goodman, a co-author, emphasized the significance of these insights for developing a tool to identify patients who might benefit from early treatment.

Dr. S. Louis Bridges Jr., another co-author, mentioned that while current RA medications may help prevent the disease, they are expensive and may have side effects. The newly identified immune cell patterns could be targets for developing more effective therapies after further validation in larger studies.